Bevacizumab Shortage Update: What Patients Need to Know in 2026

Bevacizumab in 2026: Is It Still Hard to Get?

If you're a cancer patient relying on Bevacizumab (Avastin) for treatment, you've probably heard about — or experienced — supply disruptions. Drug shortages have been a growing crisis across healthcare, and oncology drugs like Bevacizumab have been particularly affected.

Here's what you need to know about the Bevacizumab supply situation in 2026 — and what you can do to protect your treatment.

Is Bevacizumab Still in Shortage?

The short answer: it depends on which product and where you are.

Bevacizumab is now available from seven manufacturers — the original brand Avastin (Genentech) plus six FDA-approved biosimilars: Mvasi, Zirabev, Alymsys, Vegzelma, Avzivi, and Jobevne. This expanded supply has significantly improved overall availability compared to the peak shortage period in 2023-2024.

However, individual products continue to experience intermittent shortages. For example, Bevacizumab-bvzr (Zirabev) has appeared on the FDA and ASHP drug shortage lists. When a hospital or infusion center contracts primarily with one supplier and that supplier hits a snag, patients at that facility feel the impact — even if other Bevacizumab products are available elsewhere.

The overall picture is improving, but "resolved" looks different depending on where you receive your care.

Why Is Bevacizumab Hard to Find?

Several factors contribute to ongoing supply challenges:

Manufacturing Complexity

Bevacizumab is a biologic — a large, complex protein produced using living cells. Manufacturing takes months and requires specialized FDA-approved facilities. Even minor disruptions can create supply gaps that take weeks or months to recover from.

Demand Across Multiple Cancers

Bevacizumab is approved for seven different cancer types and is also used off-label for eye conditions like wet age-related macular degeneration. This broad use means demand is consistently high.

The Biosimilar Transition

While having six biosimilars is good for competition and pricing, the market is still in transition. Hospitals and payers are shifting contracts between manufacturers, and some biosimilar companies are still scaling up production capacity. This creates a "patchwork" availability where specific products come and go from the market.

Supply Chain Fragility

The oncology drug supply chain involves manufacturers, specialty distributors, group purchasing organizations, and individual healthcare facilities. A disruption at any point can create localized shortages even when national supply seems adequate.

What Does Bevacizumab Cost in 2026?

Bevacizumab remains an expensive medication, though biosimilar competition has helped bring costs down:

• Brand-name Avastin: Approximately $2,400 to $3,200 per 400 mg vial at wholesale acquisition cost (WAC)
• Biosimilars (Mvasi, Zirabev, etc.): Approximately 15-25% less than brand Avastin, with prices around $1,800 to $2,700 per 400 mg vial
• Monthly treatment cost: Depending on your dose (based on body weight) and treatment schedule, monthly costs can range from $5,000 to $15,000 or more before insurance

Most patients don't pay these full prices. Bevacizumab is typically covered under the medical benefit (not pharmacy benefit) of your insurance, since it's administered by infusion. Medicare Part B covers it at ASP (average sales price) plus 6%. Commercial insurance typically requires prior authorization.

For help with costs, see our guide on how to save money on Bevacizumab in 2026.

New Options and Developments

There is encouraging news for Bevacizumab access in 2026:

• Jobevne (bevacizumab-nwgd, by Sandoz), the sixth biosimilar, was recently FDA-approved, adding another source of supply to the market
• Biosimilar prices continue to drop as competition increases, with some products now priced 25% or more below brand Avastin
• Improved manufacturing capacity across multiple biosimilar producers is gradually stabilizing supply
• Hospitals and payers are increasingly adopting multi-source purchasing strategies, maintaining contracts with two or more Bevacizumab manufacturers to protect against shortages

How to Find Bevacizumab in Stock

If your current facility is having trouble sourcing Bevacizumab, here's what to do:

1. Use Medfinder to search for real-time availability at facilities near you
2. Ask about biosimilar substitution — if one version is out, another may be available at your facility
3. Check with other infusion centers — hospital outpatient centers and independent infusion centers often have different supply sources
4. Contact Genentech Avastin Access Solutions at (855) MY-COPAY for help locating supply
5. Plan ahead — check availability at least one week before your scheduled infusion

For a more detailed walkthrough, read our guide on how to find Bevacizumab in stock near you.

Final Thoughts

The Bevacizumab shortage situation in 2026 is improving but not fully resolved. With seven products on the market and growing manufacturing capacity, overall availability is better than it was two years ago. But individual patients can still face delays depending on their location and provider.

The best thing you can do is stay proactive. Use tools like Medfinder, communicate with your oncology team early and often, and know that biosimilar switching is safe and effective. Your cancer treatment is too important to leave to chance.

Want to understand more about this medication? Read What Is Bevacizumab? Uses, Dosage, and What You Need to Know or Why Is Bevacizumab So Hard to Find?